Grindlay Kate, Key Katherine, Zuniga Carmela, Wollum Alexandra, Blanchard Kelly, Grossman Daniel
Ibis Reproductive Health, Cambridge, Massachusetts, USA.
Ibis Reproductive Health, Oakland, California, USA.
Womens Health Rep (New Rochelle). 2022 Nov 9;3(1):904-914. doi: 10.1089/whr.2022.0056. eCollection 2022.
To assess interest in continued use of over-the-counter progestin-only pills among individuals who used them in a trial.
From January 2020 to September 2021, we conducted a cross-sectional online survey with individuals who completed participation in a trial evaluating over-the-counter use of norgestrel 0.075 mg tablets in the United States. We calculated descriptive statistics, Pearson's chi-square and Fisher's exact tests, and logistic regression models to assess likelihood of future over-the-counter progestin-only pill use, reasons for interest/noninterest, situations for over-the-counter progestin-only pill use, willingness to pay for an over-the-counter progestin-only pill, likelihood of future preventive health screenings, prior difficulties getting prescription contraception, and background characteristics.
Among 550 adult and 115 adolescent participants (75% response rate), 83% reported likelihood of future over-the-counter progestin-only pill use. Hispanic/Latinx and Black participants and adults with public insurance, prior pregnancies, and some college reported higher likelihood of future use compared with their counterparts. Among likely users, 90% were interested in long-term use and 79 % ≥ 25 years of age reported they would get future preventive screenings; participants would pay up to $20/month on average. Primary reasons for interest included convenience (81%), ease of access (80%), and saving time (77%) and money (64%). The primary reason for noninterest was bleeding associated with progestin-only pill use (52%).
There was high interest in continuing to use over-the-counter progestin-only pills among individuals who had used them in a study. These findings highlight the real-world acceptability of taking a progestin-only pill without a prescription, and contribute to evidence supporting over-the-counter access.
评估在试验中使用过非处方单方孕激素避孕药的个体继续使用该药的意愿。
2020年1月至2021年9月，我们对在美国参与一项评估0.075毫克炔诺孕酮片非处方使用情况试验的个体进行了横断面在线调查。我们计算了描述性统计量、Pearson卡方检验和Fisher精确检验，并建立了逻辑回归模型，以评估未来非处方单方孕激素避孕药的使用可能性、感兴趣/不感兴趣的原因、非处方单方孕激素避孕药的使用情况、为非处方单方孕激素避孕药付费的意愿、未来进行预防性健康筛查的可能性、之前获取处方避孕药的困难程度以及背景特征。
在550名成年参与者和115名青少年参与者中（回复率为75%），83%的人表示未来有可能使用非处方单方孕激素避孕药。与其他参与者相比，西班牙裔/拉丁裔和黑人参与者以及有公共保险、有过怀孕经历和上过一些大学的成年人未来使用的可能性更高。在可能的使用者中，90%的人对长期使用感兴趣，79%年龄≥25岁的人表示他们会进行未来的预防性筛查；参与者平均每月愿意支付20美元。感兴趣的主要原因包括方便（81%）、易于获取（80%）、节省时间（77%）和金钱（64%）。不感兴趣的主要原因是与单方孕激素避孕药使用相关的出血（52%）。
在研究中使用过非处方单方孕激素避孕药的个体对继续使用该药有很高的意愿。这些发现突出了无处方服用单方孕激素避孕药在现实世界中的可接受性，并为支持非处方获取提供了证据。
